Recombinant human hyaluronidase 1500 IU/mL (in accordance with Ph. Eur. hyaluronidase assay)
Dosage form
Injection (vial)
Technology
HYBROZYME™ Technology (Alteogen, Korea)
Product Details
Tergaze Inj. is a recombinant human hyaluronidase formulation developed based on Alteogen's proprietary recombinant technology, HYBROZYME™ Technology.
Active Ingredient
Recombinant human hyaluronidase 1500 IU/mL (In accordance with Ph. Eur. hyaluronidase assay)
Mechanism of Action and Effects
Facilitates the absorption and dispersion of drugs and local anesthetics during subcutaneous injection, intramuscular injection, and subcutaneous infusion.
Promotes the resorption of excess fluids and blood accumulated in tissues.
Product Features
High-Purity Human-Derived Hyaluronidase: Enhanced safety is expected due to the reduction of impurities and foreign proteins.
Superior Safety: Avoids the risks of viral infection and genotoxicity commonly associated with animal-derived formulations.
Recombinant DNA Technology: Manufacturing based on recombinant technology ensures uncompromised product consistency and quality stability.
Safety Evaluation: Efficacy and safety evaluations have been successfully completed in large-scale global clinical trials, including in South Korea.
Clinical Applications
Plastic Surgery: Breakdown of hyaluronic acid preparations (e.g., fillers) and management of associated side effects. When co-administered during injection therapies aimed at double chin improvement, this formulation promotes the diffusion of the drug within the tissues, contributing to a more uniform local drug distribution. It is also expected to alleviate swelling and pain associated with lifting procedures.
Internal Medicine / Oncology: Enhancement of drug delivery efficiency and tissue diffusion.
Emergency Medicine / Ophthalmology: Emergency management of conditions such as edema and hematomas.
HYBROZYME™ Technology
A proprietary subcutaneous (SC) formulation platform technology developed by the South Korean biotech company Alteogen. It plays a pivotal role in converting oncology and protein drugs—previously limited to intravenous (IV) administration—into SC formulations that enable convenient self-administration at home. This innovative technology has been successfully out-licensed to multiple leading global pharmaceutical companies.
MSD: Signed an exclusive agreement for the subcutaneous formulation of Keytruda, the world's top-selling immunotherapy.
Daiichi Sankyo: Entered into a technology partnership agreement to develop a subcutaneous formulation of Enhertu, a next-generation oncology drug.
Global Collaborations: Collaborating with more than six global pharmaceutical companies, including Sandoz and AstraZeneca.
